



NUUVERA SHORTLISTED FOR CANNABIS CONTRACT WITH THE GERMAN FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES

Toronto, Canada (January 9, 2018) – Nuuvera Inc. (“Nuuvera”) (TSXV: NUU) has been shortlisted by the German Federal Institute for Drugs and Medical Devices (BfArM) for a contract to grow, process, store and deliver up to 6000 kg of cannabis in Germany.

Over 100 interested undertakings answered BfArM’s initial call for competition. Nuuvera is one of 10 remaining bidders asked to submit an offer in the public procurement procedure.

Lorne Abony, CEO of *Nuuvera Inc.* stated, “We are tremendously excited about BfArM’s decision, and for the headway Nuuvera has made in Germany, which is one of the largest markets in the world to legalize cannabis for medical usage.”

For more information on Nuuvera, please visit: www.nuuvera.com

-30-

For media inquiries only please contact:

Justin Burrows

Venture Communications

justin@venturecommunications.ca

1-416-276-7699

About Nuuvera

Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA – Avanti Rx Analytics Inc. and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its "letter to build" approval.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Nuuvera and its business. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Nuuvera. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Nuuvera, including risks regarding the cannabis industry, failure to obtain regulatory approvals, economic factors, the equity markets generally and risks associated with growth and competition. Although Nuuvera has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results



to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made Nuuvera undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

The TSX Venture Exchange has in no way passed upon the merits of the transaction and has neither approved nor disapproved the content of this press release.